IP Library Granted Patent US 11,696,930
Granted Patent B2
US 11,696,930 · App. 16/541,091 · Granted Jul 11, 2023

Use of placental stem cells in treatment of acute kidney injury

Inventors: Steven A. Fischkoff (Short Hills, NJ); Hong-Jung Chen (Taipei, TW)
Assignee: Celularity Inc.
A61K35/50A61P13/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,696,930
App. No.
16/541,091
Granted
Jul 11, 2023
Kind
B2
Abstract

Provided herein are methods of using human placental stem cells in the treatment of subjects having acute kidney injury (AKI).

Claims (11)

1. A method of treating acute kidney injury (AKI) in a subject having AKI comprising administering to the subject a therapeutically effective amount of placental stem cells, wherein the therapeutically effective amount is an amount sufficient to cause a detectable improvement in one or more symptoms or complications of AKI, or a reduction in the progression of one or more symptoms or complications of AKI, in the subject, wherein said AKI is the result of direct trauma to one or more of the kidneys of the subject.

2. A method of preventing one or more symptoms or complications associated with acute kidney injury (AKI) in a subject having AKI comprising administering to the subject a therapeutically effective amount of placental stem cells, wherein the therapeutically effective amount is an amount sufficient to prevent the onset of one or more symptoms or complications of AKI in the subject, wherein said AKI is the result of direct trauma to one or more of the kidneys of the subject.

3. The method of claim 1 or 2 , wherein said placental stem cells are CD10+, CD34−, CD105+, CD200+ placental stem cells.

4. The method of claim 3 , wherein said placental stem cells express OCT-4.

5. The method of claim 3 , wherein said placental stem cells are additionally CD45− and CD90+.

6. The method of claim 3 , wherein said placental stem cells are additionally CD80− and CD86−.

7. The method of claim 3 , wherein the symptom associated with AKI is fatigue, bloody stool, bad breath, metallic taste in the mouth, bruising, hand tremor, high blood pressure, nosebleeds, hiccups, seizures, shortness of breath, changes in urination pattern, loss of appetite, headache, nausea and vomiting, irregular heartbeat, pain in the flanks, thirst, palpable bladder, accumulation of fluid in the limbs (peripheral edema) and/or the lungs (pulmonary edema), and/or cardiac tamponade.

8. The method of claim 7 , wherein the changes in urination pattern comprise a loss of ability to urinate regularly and/or frequent urination at night.

9. The method of claim 7 , wherein the pain in the flanks is a pain caused by thrombosis of the renal blood vessels and/or by inflammation of the kidney.

10. The method of claim 3 , wherein said method results in an increase in glomerular filtration rate, a decrease in serum creatinine level, a decrease in urine creatinine level, an increase in creatinine clearance, a decrease in the level of blood urea nitrogen (BUN), and/or a decrease in fractional excretion of sodium in the subject.

11. The method of claim 3 , wherein said placental stem cells are administered systemically, intravenously, intraarterially, or locally.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2025
From: CELULARITY INC.
To: CELENIV PTE. LTD.
Reel/Frame 073705/0109 →
MERGER Recorded Feb 24, 2023
From: ANTHROGENESIS CORPORATION
To: CLARITY ACQUISITION II LLC
Reel/Frame 062795/0601 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2023
From: CLARITY ACQUSITION II LLC
To: CELULARITY INC.
Reel/Frame 062852/0750 →